Sun Pharma has received final USFDA approval for Aspirin and Dipyridamole. This is a generic copy of Boehringer Ingelheim Pharmas drug Aggrenox, which is used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot.
Teva launched the generic of this drug in July 2015 and there are six more generic companies who have final USFDA approval to make copy of this drug (Sandoz, Barr, Par, Cadila, Amneal and ANI pharma). Sun will become eighth generic manufacture.
Aggrenox and its generics are estimated to have US sales of ~$230mn in the US and with the lower competition, we expect Sun to make $8-10mn/annum from this drug.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.